Simultaneous integrated boost of intensity‐modulated radiation therapy to Stage II‐III non‐small cell lung cancer with metastatic lymph nodes

Qing‐Song Li,Na Liang,Wei‐Wei Ouyang,Sheng‐Fa Su,Zhu Ma,Yi‐Chao Geng,Wen‐Gang Yang,Yin‐Xiang Hu,Hui‐Qin Li,Bing Lu
DOI: https://doi.org/10.1002/cam4.3446
IF: 4.711
2020-09-09
Cancer Medicine
Abstract:<p>Local tumor failure remains a major problem after radiation‐based nonsurgical treatment for unresectable locally advanced nonsmall cell lung cancer (NSCLC)and inoperable stage II NSCLC. The aim of this study was to evaluate the feasibility of simultaneous integrated boost of intensity‐modulated radiation therapy (SIB‐IMRT) to stage II‐III NSCLC with metastatic lymph nodes (ChiCTR 2000029304). Patients were diagnosed by pathology or PET‐CT. PTV was divided into two parts as follows, the PTV of primary tumor (PTVp) and the PTV of metastatic lymph nodes (PTVn). The radiotherapy doses were simultaneously prescripted 78 Gy (BED = 101.48 Gy) for PTVp and 60‐65 Gy (BED = 73.6‐81.25 Gy) for PTVn, 26f/5.2 weeks. Response was scored according to WHO criteria. Radiotherapy toxicity was scored according to RTOG criteria. Hematology and gastrointestinal toxicity were scored according to CTCAE1.0 criteria. A total of 20 patients were enrolled. Seventeen patients were diagnosed by pathology and three patients were diagnosed by PET‐CT. All patients were treated with SIB‐IMRT. The objective response rate (ORR) was 90%, with CR 25%, PR 65%, NC 10%, and PD 0%. Although radiotherapy toxicity was common, there were no grade ≥3, with radiation pneumonitis (10 cases), esophagitis (17 cases), and dermatitis (12 cases). The local control rates at 1, 3, and 5 years were 85%, 75%, and 70%, respectively. The overall survival(OS)and local progression‐free survival (LPFS) rates at 1, 3, and 5 years were 90%, 42.6%, and 35.5% and 84.4%, 35.5%, and 28.4%, respectively. SIB‐IMRT can significantly improve ORR and survival for stage II‐III NSCLC with metastatic lymph nodes, with high safety, and satisfactory efficacy. However, due to the limitation of small sample, these findings are needed to confirm by future trials with a larger sample size.</p>
oncology
What problem does this paper attempt to address?
This paper attempts to address the issue of the effectiveness and safety of using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy (SIB-IMRT) for the treatment of stage II-III non-small cell lung cancer (NSCLC) with metastatic lymph nodes in patients with unresectable locally advanced NSCLC. Specifically, the study aims to evaluate the following points: 1. **Improving local control rate**: Whether the use of SIB-IMRT can significantly improve the local tumor control rate. 2. **Improving survival rate**: Whether SIB-IMRT can improve the overall survival (OS) and local progression-free survival (LPFS) of patients. 3. **Safety assessment**: Evaluating the acute and long-term toxicity caused by SIB-IMRT during treatment, particularly the incidence of common side effects such as radiation pneumonitis, esophagitis, and dermatitis. To achieve these goals, researchers adopted different radiotherapy dose regimens, specifically administering 78 Gy (biologically effective dose BED = 101.48 Gy) to the primary tumor (PTVp) and 60-65 Gy (BED = 73.6-81.25 Gy) to the metastatic lymph nodes (PTVn), with a total treatment course of 26 sessions/5.2 weeks. Through this approach, researchers hope to improve treatment efficacy while ensuring safety.